Biocon Ltd

Business Update

Biocon Business Update

Biocon's Pertuzumab biosimilar received a positive CHMP opinion from the EMA, marking a milestone in its European regulatory path. Final European Commission approval is pending.

New Order Win

Biocon Bags New Order from Bahiafarma and Bionovis

Biocon secured a 10-year supply contract for Pertuzumab in Brazil under a government program. The partnership involves milestone payments and revenue sharing for the company.

From

Bahiafarma and Bionovis (Brazil PDP program)

Execution

10 years

Earnings Call

Biocon Investor Presentation: Key Takeaways

Biocon Q1 FY27 revenue grew 10% YoY to INR 3,433 Cr. Biopharmaceuticals grew 17% while Services declined 16%. Group EBITDA was INR 902 Cr (21% margin) and Net Profit jumped 245% to INR 145 Cr.

Earnings Call

Biocon Investor Presentation: Key Takeaways

Biocon reported Q1 FY27 revenue of ₹4,336 Cr (up 10% YoY) and Net Profit (before exceptional) of ₹145 Cr (up 245% YoY). Strategy focuses on North American biosimilar launches and generic margin expansion.

Financial Results

Biocon Q1 FY27 Results: Net Profit ₹136.8 Cr, Up 53.4% YoY

Biocon Ltd reported revenue from operations of ₹4,336 Cr (+10.0% YoY) and net profit of ₹136.8 Cr (+53.4% YoY) for Q1 FY27.

Key figure

Net profit ₹136.8 Cr · +53.4% YoY